TB-500 is the research name for a synthetic version of Thymosin β4, a naturally occurring 43-amino-acid peptide with a well-established presence in the preclinical research literature. This guide covers its mechanism, key research areas, and what researchers need to know when sourcing it.
What is TB-500?
Thymosin β4 is a naturally occurring peptide found throughout the body, with particularly high concentrations in wound fluid and platelets. TB-500 refers to the synthetic version used in research. The peptide was first isolated from thymus tissue — hence the Thymosin name — but is now understood to have a much broader distribution and range of biological activities than its thymus origin suggested.
Mechanism of action
The primary mechanism studied for TB-500 is its interaction with G-actin (monomeric actin). Thymosin β4 is one of the most abundant actin-sequestering molecules in the cell, and its role in actin dynamics has broad implications for cell migration, tissue remodelling and wound healing. Beyond actin binding, research has also examined its anti-inflammatory signalling properties and its interactions with growth factors involved in angiogenesis and tissue repair.
Key research areas
TB-500 appears in preclinical research across several tissue types. Tendon and ligament repair models are among the most studied, with research examining regenerative responses in rodent injury models. Cardiac research has explored its effects on cardiac muscle repair following ischaemic injury. Corneal and skin wound-healing models have also been studied. The common thread is its role in actin-mediated cell migration and tissue remodelling.
TB-500 and BPC-157 in combined research protocols
TB-500 is frequently studied alongside BPC-157 in tissue repair research. The two compounds have distinct but complementary mechanisms — BPC-157 operating primarily through growth factor and nitric oxide pathways, TB-500 through actin dynamics and anti-inflammatory signalling. Combined protocols allow researchers to probe multi-pathway repair mechanisms. Pepreta offers a pre-combined BPC-157 + TB-500 blend for researchers running stacked protocols.
Purity requirements
TB-500 is a 43-amino-acid peptide — longer than many research compounds — making rigorous purity characterisation essential. Truncated sequences and synthesis-related impurities are more likely at this length and can confound results if undetected. Every TB-500 batch Pepreta supplies is characterised by RP-HPLC to ≥99% purity, ESI-MS identity confirmation and LAL endotoxin screening, with a batch Certificate of Analysis available.
Sourcing TB-500 for research
Pepreta supplies TB-500 as HPLC-verified lyophilised powder in 5mg and 10mg vials, dispatched from Sydney and Melbourne. For reconstitution guidance see our reconstitution guide. Supplied for laboratory and research use only — not for human or animal consumption.